Skip to main content
European Commission logo print header

The impact of treatment with acetylcholinesterase inhibitors on Europeans with Alzheimers disease

Objetivo

AChe I have been shown to afford modest benefits on cognition in AD patients. A systematic review by the Cochrane Collaboration states "the practical importance of these changes to patients is unclear" This study's primary objective is to find clinical evidence for the global efficacy of AChE I. The secondary aim is to develop a picture of the natural history of AD. These outcomes will provide a fundamental insight into the progression and treatment of AD aiding the formulation of European guidelines. This is a prospective 2 year observational study which co-ordinates the centralisation of patient data available within the individual centres. It does not require any modification in prescribing practice of participating centres. Patients will be recruited into either a treated or non-treated patient group and reviewed 6 monthly. The primary outcome measure is a deterioration of one level on the clinical dementia rating scale.

Convocatoria de propuestas

Data not available

Coordinador

CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE
Aportación de la UE
Sin datos
Dirección
Av. de casselardit, 170
31300 Toulouse
Francia

Ver en el mapa

Coste total
Sin datos

Participantes (30)